Continuous Bioprocessing Market Size to Reach USD 1,740.0 Million in 2032
The Continuous Bioprocessing Market size was USD 367.2 Million in 2024 and is expected to register a revenue CAGR of 21.4% during the forecast period
April 22, 2025 – Technological advancements in bioprocessing is a key driver driving continuous bioprocessing market revenue growth. The production of recombinant therapeutic proteins is a complicated, diverse, and expensive process. The demand for recombinant proteins for human applications is steadily increasing. There is a high demand for new and improved bioprocessing strategies that are both cost-effective and time-efficient.
The constant enhancement of biopharmaceutical expression systems has resulted in the manufacture of quality products. Truly continuous separation methods, as opposed to semi-continuous ones, will also contribute to the advancement of continuous bioprocessing, such as continuous chromatography and viral inactivation. Continuous bioprocessing for biopharmaceutical production has the potential to lower facility and equipment footprint, as well as capital and labor costs.
On January 2022, Univercells Technologies, a leading provider of novel biomanufacturing technologies for flexible and scalable viral production, has formed a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and hMSC bioprocess systems. This collaboration will optimize extracellular vesicle (EV) manufacturing using scalable and continuous bioprocessing methods, accelerating the commercialization of regenerative medicines at a reasonable cost.
Many aspects of bioprocessing still face challenges in being implemented in a continuous mode. Downstream processes, such as cell harvesting and processing—including various filtration methods and certain chromatography techniques—largely remain in batch mode. Likewise, most upstream processes before bioreactors, such as culture media preparation and bioreactor filling, are also not yet continuous. Another significant hurdle in advancing continuous bioprocessing is the shortage of skilled professionals. As of 2023, finding experts proficient in operating continuous bioprocessing systems remains a major difficulty. For industry leaders, recruiting, training, and retaining these qualified professionals remain top priorities amid persistent concerns.
Key Highlights:
- Bioreactors segment is expected to register the largest market share over the forecast period. Continuous bioprocessing creates new opportunities for single-use technologies. Many mammalian cell culture processes now utilize continuous perfusion methods to maintain product quality, prevent degradation, and minimize both costs and working volumes. Additionally, integrating single-use bioreactors into continuous microbial applications helps lower production costs, particularly when implementing co-cultivation systems that were previously seldom used.
- Vaccine manufacturing segment is expected to account for the highest growth rate over the forecast period. Recently, there have been up to 200 ongoing clinical trials and 13 authorized drugs in the rapidly expanding biopharmaceutical sector of viral vector-based gene treatments. Continuous processing has drawn interest in the biomanufacturing sectors of vaccine and viral vector production, with potential applications for process and productivity enhancement. One-step chromatography, continuous processing with single-pass tangential flow filtering, and sustainable methods of costly reagent recycling—all of which are crucial for RNA production—could result from improved technology. Preclinical development of technologies that facilitate non-chromatographic processes, such as crystallization, is anticipated.
- North America accounted for the largest market revenue share in the continuous bioprocessing market in 2024 due to increasing demand for biologics & biosimilars, and rising adoption of single-use technologies. On June 2024, PAK BioSolutions reported that company has raised USD 12 million from Arboretum Ventures, BroadOak Capital Partners, and other investors to fund commercial and product development efforts for its line of automated continuous manufacturing systems for biologics. With this new funding, PAK will introduce the PAK PD benchtop system for smaller volume applications, processing 2-10 liters of cellular material per day, as well as the PAK K-Series system for large-scale commercial manufacturing of 20,000+ liters per day.
- Some major companies in the market report include 3M Company, Sartorius AG, Danaher Corporation, Merck KGaA, Getinge AB, Repligen Corporation, Thermo Fisher Scientific, Eppendorf SE, Kuhner AG, Wuxi Biologics, GE Healthcare, Asahi Kasei Bioprocess America, Inc., Evotec Biologics, Esco Group of Companies, and FUJIFILM Holdings Corporation.
- On February 2025, Stämm and SuperMeat collaborated to accelerate cultivated meat biomanufacturing, with Varana Capital as a mutual investor. Stämm, an innovator in biopharma production, is expanding into food technology following good results with stem cell cultivation. They use their Bioprocessor, an automated continuous bubble-free bioreactor that provides exceptional cost reductions and 15x enhanced volumetric output in biologics production. The cooperation intends to improve muscle fiber growth, elongation, and fusing into mature muscle tissue while also increasing adipocyte synthesis to provide organic whole-cut portions.
- On February 2025, Thermo Fisher Scientific Inc., the world leader in science services, said that it has reached a definitive deal with Solventum to buy the company’s Purification & Filtration business for approximately USD 4.1 billion in cash. Solventum’s purifying & filtering division is a market leader in purifying and filtering technologies utilized in biologics production, medical technology, and industrial applications.
Unlock the key to transforming your business strategy with our Continuous Bioprocessing insights
Navistrat Analytics has segmented continuous bioprocessing market based on product type, process type, application, and end-use:
- Product Type Outlook (Revenue, USD Million; 2022-2032)
- Bioreactors
- Column Bioreactor
- Tubular Bioreactor
- Stirred-Tank Bioreactor
- Permeable Wall bioreactors
- Perfusion Bioreactor
- Others
- Filtration Systems
- Tangential Flow Filtration (TFF)
- Depth filtration
- Microfiltration
- Ultrafiltration
- Chromatography Systems
- Continuous chromatography
- Simulated Moving Bed (SMB) chromatography
- Process Analytical Technologies
- Consumables & Reagents
- Chemically defined media
- Supplements & growth factors
- Tubing & connectors
- Bags & containers
- Others
- Bioreactors
- Process Type Outlook (Revenue, USD Million; 2022-2032)
-
- Upstream Processing
- Downstream Processing
- End-to-End Continuous Bioprocessing
-
- Application Outlook (Revenue, USD Million; 2022-2032)
-
- Monoclonal Antibodies (mAbs) Production
- Recombinant Protein Production
- Vaccine Manufacturing
- Cell and Gene Therapy
- Biosimilars & Biologics Production
-
- End-Use Outlook (Revenue, USD Million; 2022-2032)
-
- Pharmaceutical & Biotechnology Companies
- CDMO and CRO
- Academic & Research Institutions
-
- Regional Outlook (Revenue, USD Million; 2022-2032)
-
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America
-